Crossbow Therapeutics Doses First Patient in CBX-663 Phase 1
CAMBRIDGE, Mass. — September 9, 2026 Crossbow Therapeutics, Inc. announced dosing of the first participant in the Phase 1...
Phase 1
Advertisement
TwoStep Therapeutics Secures $62.5M and FDA IND Clearance
SAN CARLOS, Calif. — September 9, 2026 TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing alongside U.S....
Seaport Therapeutics Reports Positive Phase 1 GlyphAllo Data
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. reported positive topline results from a Phase 1 driving simulation trial...
Prelude Therapeutics Gains FDA Clearance for PRT13722
WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...
Seaport Therapeutics Advances GlyphAllo in Major Depression
BOSTON — September 9, 2026 Seaport Therapeutics, Inc. announced positive topline results from a Phase 1 driving simulation trial...
Advertisements
Pyxis Oncology Advances MICVO Toward Phase 3 in HNSCC
BOSTON — September 9, 2026 Pyxis Oncology, Inc. announced positive updated data from its ongoing Phase 1 monotherapy study...
Fate Therapeutics Presents FT819 Clinical Data at CCR-West 2026
SAN DIEGO — September 9, 2026 Fate Therapeutics, Inc. announced that new clinical data for its off-the-shelf anti-CD19 CAR...
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
Leyden Labs Advances RIG-101 Toward Phase 2 in Asthma
LEIDEN, Netherlands — September 9, 2026 Leyden Laboratories B.V. announced positive Phase 1 results for RIG-101, supporting advancement of...
Nkarta to Present Initial NKX019 Autoimmune Data at ACR 2026
SOUTH SAN FRANCISCO, California — September 8, 2026 Nkarta, Inc. announced that three scientific presentations featuring NKX019 have been...
Advertisement
